Clinical trial
A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
NCT00650572 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of ARRY-380 in Patients With Advanced HER2+ Cancer
- Lead sponsor
- Seagen Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2008
- Completion date
- March 31, 2013
- Enrollment
- 50 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
cancer